Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2026 08:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Receives Positive CHMP Opinion for LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolemia (HoFH)

Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, with European Commission (EC) decision anticipated by June 1, 2026 If approved, this would expand the indication of...
March 30, 2026 07:30 ET | Source: Medicus Pharma Ltd

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...
March 30, 2026 04:19 ET | Source: Research and Markets

Data Center Chips Market Analysis, Trends and Growth Outlook by Region, 2026-2034

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Data Center Chip Market Report by Chip Type, Data Center Size, Industry Vertical, and Region 2026-2034" has been added to ResearchAndMarkets.com's...
March 30, 2026 04:00 ET | Source: Levicept

Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis

Significant improvements in pain, function and patient global outcomes demonstratedLEVI-04 well tolerated and exhibits a favourable safety profile SANDWICH, United Kingdom, March 30, 2026 (GLOBE...
March 30, 2026 02:38 ET | Source: Trifork Group AG

22/2026・Trifork Group: Weekly report on share buyback

Schindellegi, Switzerland – 30 March 2026 Trifork Group AGCompany announcement no. 22/2026 Weekly report on share buyback On 27 February 2026, Trifork initiated a share buyback program in...
March 30, 2026 02:00 ET | Source: 4Bio Capital

4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner

Thera Liechtenstein brings extensive biotech investment and company‑building experience to new role as Partner at 4BIO CapitalTetsu Maruyama, former Head of Drug Discovery at Takeda Pharmaceuticals,...
March 28, 2026 15:00 ET | Source: MoonLake Immunotherapeutics AG

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...
March 28, 2026 15:00 ET | Source: Roivant Sciences

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in...
March 28, 2026 11:00 ET | Source: Sanofi Winthrop Industrie

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed...
March 28, 2026 11:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...